P. van Doorn

1.9k total citations · 1 hit paper
21 papers, 1.3k citations indexed

About

P. van Doorn is a scholar working on Neurology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, P. van Doorn has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Neurology, 8 papers in Cellular and Molecular Neuroscience and 6 papers in Physiology. Recurrent topics in P. van Doorn's work include Peripheral Neuropathies and Disorders (10 papers), Hereditary Neurological Disorders (8 papers) and Lysosomal Storage Disorders Research (6 papers). P. van Doorn is often cited by papers focused on Peripheral Neuropathies and Disorders (10 papers), Hereditary Neurological Disorders (8 papers) and Lysosomal Storage Disorders Research (6 papers). P. van Doorn collaborates with scholars based in Netherlands, United Kingdom and United States. P. van Doorn's co-authors include Hugh J. Willison, Richard AC Hughes, Isabel Illa, Eduardo Nobile‐Orazio, Martin Bojar, Gıancarlo Comı, Peter Van den Bergh, Marinos C. Dalakas, A V Swan and Ivo N. van Schaik and has published in prestigious journals such as PLoS ONE, Neurology and Annals of Neurology.

In The Last Decade

P. van Doorn

20 papers receiving 1.3k citations

Hit Papers

A systematic review of the global prevalence and incidenc... 2022 2026 2023 2024 2022 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A systematic review of the global prevalence and incidence of shoulder pain
    2022 106 citations P. van Doorn, Eric J. Hegedus et al. BMC Musculoskeletal Disorders profile →

Peers

P. van Doorn
Émilien Delmont France
Timothy Benstead Canada
Pierre R. Bourque Canada
Emı́lia Kerty Norway
M. Johnston Canada
Elizabeth A. Sekul United States
James Acheson United Kingdom
Alexander F. J. E. Vrancken Netherlands
H. Stephan Goedee Netherlands
Guillaume Taïeb France
Émilien Delmont France
P. van Doorn
Citations per year, relative to P. van Doorn P. van Doorn (= 1×) peers Émilien Delmont

Countries citing papers authored by P. van Doorn

Since Specialization
Citations

This map shows the geographic impact of P. van Doorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. van Doorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. van Doorn more than expected).

Fields of papers citing papers by P. van Doorn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. van Doorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. van Doorn. The network helps show where P. van Doorn may publish in the future.

Co-authorship network of co-authors of P. van Doorn

This figure shows the co-authorship network connecting the top 25 collaborators of P. van Doorn. A scholar is included among the top collaborators of P. van Doorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. van Doorn. P. van Doorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Potters, Louis, et al.. (2024). 660P Safety and efficacy of switching to avalglucosidase alfa in patients with late-onset Pompe disease previously deteriorating on alglucosidase alfa. Neuromuscular Disorders. 43. 104441.718–104441.718. 1 indexed citations
2.
3.
Hoeijmakers, Janneke G. J., Monique Hochstenbag, Myrurgia Abdul Hamid, et al.. (2023). Outcomes after robotic thymectomy in nonthymomatous versus thymomatous patients with acetylcholine-receptor-antibody-associated myasthenia gravis. Neuromuscular Disorders. 33(5). 417–424. 7 indexed citations
4.
Doorn, P. van, et al.. (2022). A systematic review of the global prevalence and incidence of shoulder pain. BMC Musculoskeletal Disorders. 23(1). 1073–1073. 106 indexed citations breakdown →
5.
Harlaar, Laurike, Jean‐Yves Hogrel, Barbara Perniconi, et al.. (2019). O.23A 10 year prospective study on the effects of enzyme replacement therapy in adult Pompe patients. Neuromuscular Disorders. 29. S122–S122.
6.
Davidson, Amy, Susan K. Halstead, John A. Goodfellow, et al.. (2016). Inhibition of complement in Guillain‐Barré syndrome: the ICA‐GBS study. Journal of the Peripheral Nervous System. 22(1). 4–12. 55 indexed citations
7.
Berg, Linda van den, Marein M. Favejee, Stephan C.A. Wens, et al.. (2013). Effects of exercise training in 23 adults with Pompe disease receiving enzyme therapy. BMC Musculoskeletal Disorders. 14(S2). 1 indexed citations
8.
Güngör, Deniz, Esther Brusse, Michelle E. Kruijshaar, et al.. (2013). Enzyme replacement therapy and fatigue in adults with Pompe disease. BMC Musculoskeletal Disorders. 14(S2). 4 indexed citations
9.
Rinaldi, Simon, Kathryn M. Brennan, Gabriela Kalna, et al.. (2013). Antibodies to Heteromeric Glycolipid Complexes in Guillain-Barré Syndrome. PLoS ONE. 8(12). e82337–e82337. 57 indexed citations
10.
Koski, Carol Lee, Mona Baumgarten, LS Magder, et al.. (2008). Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences. 277(1-2). 1–8. 102 indexed citations
11.
Elovaara, Irina, Slobodan Apostolski, P. van Doorn, et al.. (2008). EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. European Journal of Neurology. 15(9). 893–908. 200 indexed citations
12.
Hagemans, M.L.C., et al.. (2007). M.P.2.06 Gradual disease progression during long-term follow up of patients with late-onset Pompe disease. Neuromuscular Disorders. 17(9-10). 794–794. 1 indexed citations
13.
Hagemans, M.L.C., et al.. (2007). Pompe Disease: A Continuum of Clinical Phenotypes. Clinical Therapeutics. 29. S103–S104. 1 indexed citations
14.
15.
Hughes, Richard AC, Hugh J. Willison, Peter Van den Bergh, et al.. (2001). Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology. 50(2). 195–201. 483 indexed citations
16.
Visser, Loes E., et al.. (1998). Risk factors for treatment related clinical fluctuations in Guillain-Barre syndrome. Journal of Neurology Neurosurgery & Psychiatry. 64(2). 242–244. 50 indexed citations
17.
Badrising, Umesh A., Marion L. C. Maat–Schieman, Sjoerd G. van Duinen, et al.. (1997). The onset and distribution of muscle weakness in inclusion body myositis (IBM). Neuromuscular Disorders. 7(6-7). 464–464. 1 indexed citations
18.
Badrising, Umesh A., Marion L. C. Maat–Schieman, Sjoerd G. van Duinen, et al.. (1997). Epidemiology of inclusion body myositis in the Netherlands. Neuromuscular Disorders. 7(6-7). 463–464. 2 indexed citations
19.
Doorn, P. van. (1990). Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. 12 indexed citations
20.
Doorn, P. van, et al.. (1987). Hyperventilation and panic attacks.. PubMed. 48(11). 435–7. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Émilien Delmont Breakdown of academic impact, for papers by Timothy Benstead Breakdown of academic impact, for papers by Pierre R. Bourque Breakdown of academic impact, for papers by Emı́lia Kerty Breakdown of academic impact, for papers by M. Johnston Breakdown of academic impact, for papers by Elizabeth A. Sekul Breakdown of academic impact, for papers by James Acheson Breakdown of academic impact, for papers by Alexander F. J. E. Vrancken Breakdown of academic impact, for papers by H. Stephan Goedee Breakdown of academic impact, for papers by Guillaume Taïeb
Rankless by CCL
2026